A trio of novel cancer agent applications announced last week illustrates the breadth of oncology R&D, from targeted kinase inhibitors (Taiho Pharmaceutical Co. Ltd.’s futibatinib) to antibody-drug conjugates (ImmunoGen, Inc.’s mirvetuximab soravtansine) and radioimmunotherapy (Y-mAbs Therapeutics Inc.’s 131I-omburtamab).
Keeping Track: Novel Oncologics Submitted By Taiho, ImmunoGen, Y-mAbs; US FDA Declines Akebia’s Vadadustat
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
